Genfit S.A./€GNFT
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Genfit S.A.
Genfit S.A. is a French biopharmaceutical company focused on developing therapeutics and diagnostic solutions for metabolic and liver-related diseases. Known for its work in treating nonalcoholic steatohepatitis (NASH) and other liver diseases, Genfit offers key products including investigational drugs such as elafibranor and diagnostic tests like NIS4 for identifying NASH. Founded in 1999, the company is headquartered in Loos, France. Its strategic positioning lies in addressing unmet medical needs in liver health, supported by a robust research and development pipeline. Genfit's competitive strengths include expertise in nuclear receptor pathways and strategic partnerships with other biopharmaceutical firms.
Ticker
€GNFT
Sector
Primary listing
PAR
Employees
188
Headquarters
Website
Genfit S.A. Metrics
BasicAdvanced
€402m
-
-€1.72
1.14
-
Price and volume
Market cap
€402m
Beta
1.14
52-week high
€9.51
52-week low
€3.23
Average daily volume
13k
Financial strength
Current ratio
1.995
Quick ratio
1.956
Long term debt to equity
-478.297
Total debt to equity
-668.655
Interest coverage (TTM)
-44.69%
Profitability
EBITDA (TTM)
-51.789
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-131.38%
Operating margin (TTM)
-81.96%
Effective tax rate (TTM)
0.61%
Revenue per employee (TTM)
€350,000
Management effectiveness
Return on assets (TTM)
-21.59%
Return on equity (TTM)
-368.27%
Valuation
Price to revenue (TTM)
6.176
Price to book
-17.99
Price to tangible book (TTM)
-15.19
Price to free cash flow (TTM)
-13.623
Free cash flow yield (TTM)
-7.34%
Free cash flow per share (TTM)
-0.593
Growth
Revenue change (TTM)
-7.44%
Earnings per share change (TTM)
-5,833.33%
3-year revenue growth (CAGR)
35.60%
10-year revenue growth (CAGR)
31.46%
3-year earnings per share growth (CAGR)
53.03%
10-year earnings per share growth (CAGR)
9.17%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genfit S.A. stock?
Genfit S.A. (GNFT) has a market cap of €402M as of May 01, 2026.
What is the P/E ratio for Genfit S.A. stock?
The price to earnings (P/E) ratio for Genfit S.A. (GNFT) stock is 0 as of May 01, 2026.
Does Genfit S.A. stock pay dividends?
No, Genfit S.A. (GNFT) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Genfit S.A. dividend payment date?
Genfit S.A. (GNFT) stock does not pay dividends to its shareholders.
What is the beta indicator for Genfit S.A.?
Genfit S.A. (GNFT) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.